scPharmaceuticals (NASDAQ:SCPH) Issues Earnings Results

scPharmaceuticals (NASDAQ:SCPH) posted its quarterly earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09, Zacks reports. The business had revenue of $6.10 million during the quarter, compared to analyst estimates of $6.50 million. scPharmaceuticals had a negative net margin of 403.22% and a negative return on equity of 97.18%. During the same quarter in the previous year, the business posted ($0.30) EPS.

scPharmaceuticals Stock Up 0.7 %

Shares of scPharmaceuticals stock traded up $0.03 on Thursday, reaching $4.60. The stock had a trading volume of 8,030 shares, compared to its average volume of 219,461. scPharmaceuticals has a 1 year low of $4.01 and a 1 year high of $11.75. The company has a 50 day moving average price of $4.91 and a 200 day moving average price of $5.39. The company has a quick ratio of 6.40, a current ratio of 7.08 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $165.83 million, a P/E ratio of -3.30 and a beta of 0.09.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research note on Wednesday.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.